Homepage
Kanghong Biotech focuses on developing new drugs for aesthetic medicine and chronic inflammatory diseases.

Caliway Biopharmaceuticals is a small-molecule drug discovery company developing therapeutics for medical aesthetics and inflammatory disease.
caliwaybiopharma.comCrawled Nov 6, 2026
Kanghong Biotech focuses on developing new drugs for aesthetic medicine and chronic inflammatory diseases.
Caliway Biopharmaceuticals reports its Phase 2 trial of **CBL-514** for **Dercum’s Disease** meets the primary endpoint, showing **statistically significant and sustained pain reduction** in patients. The randomized, single-blind, placebo-controlled study (CBL-0202DD) evaluates the drug’s efficacy against the rare, painful lipoma disorder. Results confirm clinically meaningful improvements, advancing potential treatment options for affected individuals.
Caliway Biopharmaceuticals secures U.S. FDA clearance for a Phase 2 trial of **CBL-514**, its first-in-class local fat-reducing drug, combined with Eli Lilly’s **Zepbound® (Tirzepatide)**. The company also begins enrollment for its pivotal **Phase 3 trial, SUPREME-01**, advancing its clinical-stage small-molecule therapeutics pipeline. Both milestones mark progress in Caliway’s drug development program targeting fat reduction.
Caliway presents preclinical data showing **CBL-514**, when combined with **semaglutide** or **tirzepatide**, enhances weight loss and reduces fat accumulation in animal studies. The findings also highlight its potential to improve liver metabolic indicators, marking the first disclosure of this effect at an international congress. The presentation has drawn strong interest from global pharmaceutical companies and experts evaluating its systemic metabolic benefits.
Caliway Biopharmaceuticals secures FDA approval for its Phase 3 trial design of **CBL-514**, a first-in-class injectable drug targeting large-area subcutaneous fat reduction. The End-of-Phase 2 meeting confirms pivotal trial endpoints and supports the upcoming New Drug Application (NDA) filing. The drug candidate aims to address abdominal fat reduction, a key unmet need in metabolic health.
Caliway Biopharmaceuticals raises over $100 million in an oversubscribed funding round by issuing 8 million new shares. The capital supports the advancement of its **CBL-514** drug candidate through a **Phase 3 pivotal study** targeting subcutaneous fat reduction. The company aims to further clinical development in this therapeutic area.